A double trial success from Roche sees it eyeing a combination therapy in lucrative first-line lung cancer, and wider use of its just-approved haemophilia drug, Hemlibra.
The WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for 8.8 million fatalities, yet we are at a point in time where the speed of advancement in underst
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
